Skip to main content
Medical information Clinical review pending

Genetic Testing

CD3G Gene Cone-Rod Dystrophy Type 17 Genetic Test

Genetic test using Next Generation Sequencing (NGS) to identify mutations in the CD3G gene associated with Cone-Rod Dystrophy Type 17, a rare inherited eye disorder causing progressive vision loss. Helps with early diagnosis and management.

General information only: This page is not a diagnosis or personal medical advice. A qualified clinician should decide whether testing is appropriate and interpret results in context.

Review status: No completed medical review is recorded for this page.

Ask a question
Counselor guidance included Confidential handling Kenya-wide coordination

At a glance

Plan your test

Sample
Blood sample, Extracted DNA, or One drop of blood on an FTA card.
Results
Confirm with the laboratory before booking.
Preparation
A clinical history of the patient is required. A genetic counseling session is recommended prior to testing to discuss the test and create a family pedigree.
Test priceKSh 40,000

Payment: M-Pesa and card options can be confirmed during booking.

Insurance & government schemes

Is this test covered for you?

We help you verify whether the CD3G Gene Cone-Rod Dystrophy Type 17 Genetic Test test can be claimed against your insurer, employer scheme or a Kenyan government health scheme — before you book. Coverage depends on your plan, clinical indication and your provider's rules; final approval always rests with them.

Talk to a claims advisor

Providers & schemes we can help you check

Government & public schemes

SHIF — Social Health Insurance Fund Linda Mama EduAfya NHIF (legacy cards)

Eligibility and benefits follow the current rules of the Social Health Authority (SHA) and applicable government programmes.

Private insurers & employer schemes

Jubilee Health AAR APA Britam CIC Madison Resolution Pioneer Minet Old Mutual GA Life Heritage + other licensed insurers

Names shown for identification only — listing does not imply partnership or guarantee of coverage.

Have these ready when we check

  • Insurer or scheme name & policy / member number
  • A clinician's request / prescription for the test
  • Pre-authorisation letter, if your plan requires one

Free coverage check

Ask us to verify your cover

Send your details and our claims team confirms what documents you need and whether pre-authorisation applies — usually the same working day.

+254

Used only to process your coverage check — see our Privacy Policy. Verification support is free and does not guarantee your provider will pay.

01

Start with fit

Is this the right test for you?

The best test starts with a clear clinical question. These are common reasons a clinician or family may consider this test.

  • ✓Progressive vision loss
  • ✓Difficulty seeing in low light
  • ✓Color vision deficiencies
  • ✓Family history of retinal disorders
  • ✓Suspected inherited eye condition
  • ✓Genetic counseling for family planning
02

In plain language

What this test helps you understand

This test helps identify specific genetic mutations in the CD3G gene that cause Cone-Rod Dystrophy Type 17. Identifying these mutations can confirm a diagnosis, aid in understanding the specific type of retinal dystrophy, and potentially inform prognosis and management strategies. It can also be used for genetic counseling within families.
The CD3G Gene Cone-Rod Dystrophy Type 17 NGS Genetic DNA Test is a specialized diagnostic tool used to detect genetic mutations linked to cone-rod dystrophy, a condition characterized by the progressive degeneration of photoreceptor cells in the retina, leading to vision loss. This test utilizes advanced Next Generation Sequencing (NGS) technology to analyze the CD3G gene. Understanding your genetic status can be important for early intervention and managing the condition. This test is particularly relevant for individuals with symptoms suggestive of retinal disorders or a family history of such conditions.
03

Medical review status

Clinical review pending

A completed medical review is not recorded for this page. No clinician has endorsed the information shown here. Please discuss testing decisions with a qualified healthcare professional.

Meet the DNA Labs Kenya medical team →
04

A simple process

What happens next?

You do not have to navigate the test alone. We help you move from question to next step.

1

Speak with us

We check the test and answer your questions before collection.

2

Give your sample

Choose home collection or a coordinated hub visit in Kenya. We explain whether this test uses a cheek swab or blood draw.

3

Understand your report

A counselor helps you understand the result and the next steps.

05

Choose your collection

Home collection or a lab visit

We will explain the sample, preparation, and next steps before anything is collected.

Home collection

Choose a coordinated visit at home or another convenient location. Our team confirms the appointment and sample requirements in advance.

Lab or hub visit

Prefer to visit a coordinated location? We can guide you to the right hub and explain what to expect when you arrive.

Ask about locations →
PreparationA clinical history of the patient is required. A genetic counseling session is recommended prior to testing to discuss the test and create a family pedigree.
SampleBlood sample, Extracted DNA, or One drop of blood on an FTA card.
MethodologyNext Generation Sequencing (NGS) analysis of the CD3G gene.
PrivacyYour sample and report are handled confidentially. Ask the team how your information is stored and shared.
This test specifically analyzes the CD3G gene. Other genes can also cause cone-rod dystrophy. A negative result does not completely rule out a genetic cause for the symptoms. Confirm with the laboratory before booking.
06

Read your report

What common result terms mean

PositiveA finding was identified. Your clinician or counselor will explain what it means for your care.
NegativeThe specific finding tested for was not identified. It does not rule out every possible cause.
VUSA variant was found, but current evidence is not enough to classify it. Your counselor can explain follow-up.
07

Questions people ask

Frequently asked questions

Cone-Rod Dystrophy Type 17 is a rare inherited eye disorder caused by mutations in the CD3G gene. It leads to the progressive loss of vision due to the degeneration of cone and rod cells in the retina.
Individuals experiencing symptoms like progressive vision loss, night blindness, or color vision problems, especially with a family history of retinal disorders, may be candidates for this test.
The test involves analyzing a sample of your blood or DNA using Next Generation Sequencing (NGS) technology to look for mutations in the CD3G gene.
Results will indicate whether specific mutations in the CD3G gene were found. A genetic counselor can help explain the results and their implications for you and your family.
Yes, genetic counseling before and after testing is highly recommended to understand the test, its implications, and discuss family planning options.
Insurance coverage for genetic testing varies. Please check with your insurance provider regarding coverage for this specific test.
08

Collaboration

Open for partnership with hospitals, clinics, doctors & researchers

Whether you are referring patients, building a research programme or supporting students, we work as an extension of your team — with responsive communication and clear scientific standards.

Hospitals & clinics

Referral pathways, coordinated sample logistics and shared reporting that fits your clinical workflow.

Doctors & specialists

LOINC-coded reports, ACMG-based variant classification and a direct scientific line for complex cases.

Research institutions

Sanger sequencing, NGS panels and custom assays — with project design support, batch pricing and agreed turnaround commitments.

Students & academic projects

Discounted laboratory services for college, master's and PhD research projects — including proposal guidance and cost-effective batch testing.

Explore partnerships
09

Trust & transparency

Sources, standards & how this page is maintained

Standards & references

  • ACMG/AMP technical standards for sequence variant interpretation
  • ClinGen curation and gene–disease validity frameworks where applicable
  • LOINC-coded reporting for interoperable results
  • ISO 9001:2015 quality management; ISO 15189 accreditation in progress

Page provenance

  • Last updated: September 27, 2026
  • Medical review: not yet completed
  • Written for patients & clinicians in Kenya; reviewed periodically against current guidance

Medical disclaimer: this page is general information, not a diagnosis or personal medical advice. Testing decisions and result interpretation should be made with a qualified healthcare professional.

Keep exploring

Related tests

View all tests →
Chat on WhatsApp